-
公开(公告)号：US20120122858A1
公开(公告)日：2012-05-17
申请号：US13355219
申请日：2012-01-20
申请人： Wenqing Yao , Chunhong He , David M. Burns , Jincong Zhuo , Meizhong Xu , Colin Zhang , Ding-Quan Qian , Brian Metcalf
发明人： Wenqing Yao , Chunhong He , David M. Burns , Jincong Zhuo , Meizhong Xu , Colin Zhang , Ding-Quan Qian , Brian Metcalf
IPC分类号： A61K31/5355 , A61K31/438 , A61K31/496 , A61K31/506 , A61K31/4725 , A61K31/4709 , A61K31/497 , A61K31/52 , A61K31/517 , C07D487/04 , A61K31/519 , A61P3/04 , A61P3/10 , A61P3/08 , A61P9/12 , A61P3/06 , A61P25/00 , A61P25/24 , A61P25/28 , A61P27/06 , A61P9/00 , A61P19/10 , A61P29/00 , A61P13/12 , A61P9/04 , A61P9/10 , A61P7/02 , A61P3/00 , C07D471/10
CPC分类号： C07D471/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及11-和bgr的抑制剂。 1型羟基类固醇脱氢酶，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病。
-
公开(公告)号：US20120015928A1
公开(公告)日：2012-01-19
申请号：US13243565
申请日：2011-09-23
申请人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
发明人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
IPC分类号： A61K31/40 , C07D221/20 , A61K31/438 , C07D471/10 , C07D241/04 , A61K31/495 , C07D401/06 , A61K31/496 , C07D413/14 , A61K31/5377 , C07D295/112 , A61K31/55 , A61K31/4439 , A61P3/04 , A61P3/10 , A61P3/08 , A61P5/48 , A61P9/12 , A61P3/06 , A61P25/28 , A61P27/06 , A61P9/00 , A61P19/10 , A61P29/00 , A61P13/12 , A61P9/04 , A61P7/02 , A61P7/00 , A61P3/00 , A61P9/10 , C12N9/99 , C07D207/12
CPC分类号： C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及11-和bgr的抑制剂。 1型羟基类固醇脱氢酶，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病。
-
公开(公告)号：US07776874B2
公开(公告)日：2010-08-17
申请号：US12136529
申请日：2008-06-10
申请人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
发明人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
IPC分类号： A61K31/443 , A61K31/4025 , A61K31/34 , C07D213/46 , C07D209/54 , C07D407/10
CPC分类号： C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及11-和bgr的抑制剂。 1型羟基类固醇脱氢酶，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病。
-
公开(公告)号：US08461330B2
公开(公告)日：2013-06-11
申请号：US12813148
申请日：2010-06-10
申请人： Jincong Zhuo , Meizhong Xu , Chunhong He , Colin Zhang , Ding-Quan Qian , David M. Burns , Yun-Long Li , Brian Metcalf , Wenqing Yao
发明人： Jincong Zhuo , Meizhong Xu , Chunhong He , Colin Zhang , Ding-Quan Qian , David M. Burns , Yun-Long Li , Brian Metcalf , Wenqing Yao
IPC分类号： C07D487/04 , C07D403/04 , C07D403/14 , A61K31/53 , A61K31/5377 , A61P35/00
CPC分类号： C07D487/04 , A61K31/4709 , A61K31/53 , C07D403/06
摘要： The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
摘要翻译： 本发明涉及咪唑并[1,2-b] [1,2,4]三嗪和咪唑并[1,2-a]嘧啶及其药物组合物，它们是诸如c-Met的激酶抑制剂， 可用于治疗与激酶途径失调相关的癌症和其它疾病。
-
公开(公告)号：US08193207B2
公开(公告)日：2012-06-05
申请号：US11633347
申请日：2006-12-04
申请人： Jincong Zhuo , Ding-Quan Qian , Wenqing Yao
发明人： Jincong Zhuo , Ding-Quan Qian , Wenqing Yao
IPC分类号： A61K31/438 , C07D471/10
CPC分类号： C07D471/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.
摘要翻译： 本发明涉及11-和bgr的抑制剂。 羟基类固醇脱氢酶1型及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型。
-
公开(公告)号：US20110144113A1
公开(公告)日：2011-06-16
申请号：US13033918
申请日：2011-02-24
申请人： Jincong Zhuo , Colin Zhang , Meizhong Xu , Ding-Quan Qian , Wenqing Yao , Ravi Kumar Jalluri
发明人： Jincong Zhuo , Colin Zhang , Meizhong Xu , Ding-Quan Qian , Wenqing Yao , Ravi Kumar Jalluri
IPC分类号： A61K31/53 , C12N9/99 , C12N5/02 , C07D487/04 , A61P21/00 , A61P35/04 , A61P37/08 , A61P29/00 , A61P11/00 , A61P41/00 , A61P9/00
CPC分类号： C07D487/04
摘要： The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
摘要翻译： 本发明涉及[1,2,4]三唑并[4,3-b] [1,2,4]三嗪及其药物组合物，其为激酶抑制剂，例如c-Met，可用于 治疗与激素途径失调相关的癌症和其他疾病。
-
公开(公告)号：US20100256114A1
公开(公告)日：2010-10-07
申请号：US12817887
申请日：2010-06-17
申请人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
发明人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian W. Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
IPC分类号： A61K31/55 , C07D207/12 , A61K31/40 , C07D211/06 , A61K31/445 , A61K31/47 , C07D401/02 , A61K31/4439 , C07D403/02 , A61K31/497 , C07D217/00 , C07D209/44 , A61K31/4035 , C07D209/96 , A61K31/407 , C07D277/00 , A61K31/426 , C07D263/00 , A61K31/421 , C07D213/02 , A61K31/465 , C07D451/02 , A61K31/46 , C07D265/04 , A61K31/535 , C07D223/02 , C07D223/14 , A61P9/00 , A61P3/06 , A61P3/10
CPC分类号： C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要翻译： 本发明涉及11-和bgr的抑制剂。 1型羟基类固醇脱氢酶，盐皮质激素受体（MR）的拮抗剂及其药物组合物。 本发明的化合物可用于治疗与11-bgr的表达或活性相关的各种疾病; 羟基类固醇脱氢酶1型和/或与醛固酮过量相关的疾病。
-
公开(公告)号：US20080039457A1
公开(公告)日：2008-02-14
申请号：US11834226
申请日：2007-08-06
申请人： Jincong Zhuo , Colin Zhang , Meizhong Xu , Ding-Quan Qian , Wenqing Yao , Ravi Jalluri
发明人： Jincong Zhuo , Colin Zhang , Meizhong Xu , Ding-Quan Qian , Wenqing Yao , Ravi Jalluri
IPC分类号： A61K31/53 , A61K31/5377 , A61P29/00 , A61P35/00 , A61P37/00 , A61P9/00 , C07D487/04
CPC分类号： C07D487/04
摘要： The present invention is directed to [1,2,4]triazolo[4,3-b][1,2,4]triazines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
摘要翻译： 本发明涉及[1,2,4]三唑并[4,3-b] [1,2,4]三嗪及其药物组合物，其为激酶抑制剂，例如c-Met，可用于 治疗与激素途径失调相关的癌症和其他疾病。
-
公开(公告)号：US20060116382A1
公开(公告)日：2006-06-01
申请号：US11269984
申请日：2005-11-09
申请人： Wenqing Yao , Chunghong He , Jincong Zhuo , Meizhong Xu , Colin Zhang , Ding-Quan Qian , David Burns , Brian Metcalf
发明人： Wenqing Yao , Chunghong He , Jincong Zhuo , Meizhong Xu , Colin Zhang , Ding-Quan Qian , David Burns , Brian Metcalf
IPC分类号： A61K31/52 , A61K31/496 , A61K31/4747 , C07D473/02 , C07D487/04
CPC分类号： C07D221/20 , C07D471/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
-
公开(公告)号：US20050282858A1
公开(公告)日：2005-12-22
申请号：US11122309
申请日：2005-05-04
申请人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
发明人： Wenqing Yao , Jincong Zhuo , Meizhong Xu , Brian Metcalf , Chunhong He , Ding-Quan Qian , Colin Zhang
IPC分类号： A61K31/401 , A61K31/445 , C07D207/06 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/263 , C07D207/30 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/00 , C07D221/20 , C07D223/02 , C07D223/04 , C07D231/04 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
CPC分类号： C07D207/06 , A61K31/407 , A61K31/4439 , C07D207/08 , C07D207/10 , C07D207/12 , C07D207/14 , C07D207/16 , C07D207/27 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/52 , C07D209/62 , C07D209/70 , C07D211/16 , C07D211/18 , C07D211/22 , C07D211/34 , C07D211/46 , C07D211/48 , C07D211/52 , C07D211/58 , C07D211/64 , C07D211/66 , C07D211/70 , C07D213/38 , C07D217/06 , C07D217/26 , C07D221/20 , C07D295/185 , C07D333/34 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/04 , C07D405/04 , C07D405/14 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D491/107 , C07D491/20 , C07D493/10 , C07D495/04 , C07D498/20 , C07D513/10
摘要： The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.049 秒)
